Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO Breast Cancer Virtual Congress 2021, 5-8 May April 28, 2021 Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... February 25, 2021 Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... December 17, 2020 College Basketball Star Plays First Game in Nearly Two Years After... December 1, 2020 Load more HOT NEWS A More Treatable Kind of Metastatic Cancer? Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates... A College Senior vs. A Global Pandemic FDA Approves Dostarlimab-gxly with Chemotherapy for Endometrial Cancer
